2004
1. Espirito Santo S.M., N.M.
Pires, L.S. Boesten, G. Gerritsen, N. Bovenschen , K. Willems van Dijk, J.W.
Jukema, H.M. Princen, A. Bensadoun , W.P. Li , J. Herz, L.M. Havekes, and
B.J. van Vlijmen. Hepatic low-density lipoprotein receptor-related protein
deficiency in mice increases atherosclerosis independent of plasma
cholesterol. 2004. Blood. 103: 3777-82.
2. Schaap, F.G., P.J. Voshol,
P.C.N. Rensen, H.N. van der Vliet, R.A.F.M. Chamuleau, N. Maeda, L.M.
Havekes, A.K. Groen and K. Willems van Dijk. 2004. ApoAV expression
ameliorates type III hyperlipidemia in mouse models by stimulating
lipoprotein lipase-mediated VLDL-triglyceride hydrolysis. J. Biol. Chem.
279:27941-7.
3. Goudriaan J.R., S.M. Espirito
Santo, P.J. Voshol, B. Teusink , K. Willems Van Dijk , B.J. van Vlijmen,
J.A.Romijn, L.M. Havekes, and P.C. Rensen. 2004. The VLDL receptor plays a
major role in chylomicron metabolism by enhancing LPL-mediated triglyceride
hydrolysis. J Lipid Res. 45:1475-81
4. Willems van Dijk, K., P.C.N.
Rensen, P.J. Voshol, and L.M. Havekes. 2004.The role and mode of action of
apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?
Cur.Opin. Lipidol.15:239-46.
5. Bovenschen N, Willems van Dijk
K, Havekes LM, Mertens K, van Vlijmen BJ. Clearance of coagulation factor
VIII in very low-density lipoprotein receptor knockout mice. Br J
Haematol. 2004. 126:722-5.
2003
1. Gerritsen, G., K.E. Kypreos,
A. van der Zee, B. Teusink, V.I. Zannis, L.M. Havekes, K. Willems van Dijk.
2003. Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated
apoE variant lacking the C-terminal domain. J. Lipid Res. 44: 408
2. Kypreos, K.E., X. Li, K.
Willems van Dijk, L.M. Havekes, V.I. Zannis. 2003. Molecular mechanisms of
type III hyperlipoproteinemia: the contribution of the carboxy-terminal
domain of apoE can account for the dyslipidemia that is associated with the
E2/E2 phenotype. Biochemistry. 42: 9841.
3. Willems van Dijk, K., K.E.
Kypreos, C. d’Oliveira, F. Fallaux. 2003. Adenovirus mediated gene transfer.
M. Hofker and J van Deursen (Eds). Transgenic mouse methods and protocols.
Methods Mol. Biol. 209: 231
2002
1.Tacken, P.J., D.J.M. Delsing,
M.J.J. Gijbels, P.H.A. Quax, L.M. Havekes, M.H. Hofker, K. Willems van Dijk.
2002. VLDL receptor deficiency enhances intimal thickening after vascular
injury but does not affect atherosclerotic lesion area. Atherosclerosis.
162: 103
2001
1. Van Eck, M., K. Willems van
Dijk, N. Herijgers, M.H. Hofker, P.H. Groot, T.J. van Berkel. 2001.
Essential role for the (hepatic) LDL receptor in macrophage apolipoprotein
E-induced reduction in serum cholesterol levels and atherosclerosis.
Atherosclerosis. 154:103
2. Kypreos*, K.E., K. Willems van
Dijk*, A. van der Zee, L.M. Havekes, V.I. Zannis. 2001. Domains of
apolipoprotein E contributing to triglyceride and cholesterol homeostasis in
vivo: the carboxylterminal region 203-299 promotes hepatic VLDL-triglyceride
secretion. J. Biol. Chem. 276: 19778 *Shared first authorship.
3. Jaari S., K. Willems van Dijk,
V.M. Olkkonen, A. van der Zee, J. Metso, L. Havekes, M. Jauhiainen, C.
Ehnholm. 2001. Dynamic changes in mouse lipoproteins induced by transiently
expressed human phospholipid transfer protein (PLTP): importance of PLTP in
prebeta-HDL generation. Comp. Biochem. Physiol. B. Biochem. Mol. Biol.128:781.
4. Tacken, P.J., A. van der Zee,
T.L. Beumer, R.L. Florijn, M.J.J. Gijbels, L.M. Havekes, R.R. Frants, K.
Willems van Dijk, M.H. Hofker. 2001. Effective generation of low density
lipoprotein receptor transgenic mice by overlapping genomic DNA fragments:
high testis expression and disturbed spermatogenesis. Transgenic Res.
10:211
5. Tacken, P.J., M.H. Hofker, L.M. Havekes, K. Willems van Dijk. Living up
to a name: the role of the VLDL receptor in lipid metabolism. 2001. Curr.
Opin. Lipidol. 12:275.
6. Kypreos, K.E., B. teusink, K.
Willems van Dijk, L.M. Havekes, V.I. Zannis. 2001. Analysis of the structure
and function relationship of the human apolipoprotein E in vivo, using
adenovirus-mediated gene transfer. FASEB J. Express article: 10.1096/fj.00-0882fje,
printed version: FASEB J. 2001 15:1598
7. Kypreos, K.E., P. Morani, K. Willems van Dijk, L.M. Havekes, V.I. Zannis.
The aminoterminal 1-185 domain of apoE promotes the clearance of lipoprotein
remnants in vivo. The carboxyterminal domain is required for induction of
hyperlipidemia in normal and apoE-deficient mice. 2001. Biochemistry.
40:6027
8. Mensenkamp A.R., B. Teusink,
J.F. Baller, H. Wolters, R. Havinga, K. Willems van Dijk, L.M. Havekes, F.
Kuipers. 2001. Mice expressing only the mutant apoe3leiden gene show
impaired vldl secretion. Arterioscler. Thromb. Vasc. Biol. 21:1366
9. Goudriaan, J.R., P.J. Tacken,
V.E.H. Dahlmans, M.J.J. Gijbels, K. Willems van Dijk, L.M. Havekes, M.C.
Jong. 2001. Protection from obesity in mice lacking the VLDL receptor.
Arterioscler. Thromb. Vasc. Biol. 21:1488
10. Teusink b., A.R. Mensenkamp, H. van der Boom, F. Kuipers, K. Willems van
Dijk, and L.M. Havekes Stimulation of the in vivo production of very low
density lipoproteins by apolipoprotein E is independent of the presence of
the LDL receptor. 2001. J. Biol. Chem. 276: 40693
2000
1. Willems Van Dijk K, Hofker MH, Havekes LM. Use of transgenic mice
to study the role of apolipoprotein E in lipid metabolism and
atherosclerosis. Int J Tissue React 2000;22(2-3):49-58.
2. van Eck M, Herijgers N, Willems van Dijk K, Havekes LM, Hofker MH,
Groot PH, Van Berkel TJ. Effect of macrophage-derived mouse ApoE, human
ApoE3-Leiden, and human ApoE2 (Arg158-->Cys) on cholesterol levels and
atherosclerosis in ApoE- deficient mice. Arterioscler Thromb Vasc Biol
2000;20(1):119-27.
3. Tacken PJ, Beer FD, Vark LC, Havekes LM, Hofker MH, Willems Van
Dijk K. Very-low-density lipoprotein binding to the apolipoprotein E
receptor 2 is enhanced by lipoprotein lipase, and does not require
apolipoprotein E. Biochem J 2000;347(Pt 2):357-361.
4. de Winther MP, Gijbels MJ, Willems van Dijk K, Havekes LM, Hofker
MH. Transgenic mouse models to study the role of the macrophage scavenger
receptor class A in atherosclerosis. Int J Tissue React
2000;22(2-3):85-91.
5. de Winther MP, van Dijk KW, Havekes LM, Hofker MH. Macrophage
scavenger receptor class A : A multifunctional receptor in atherosclerosis. Arterioscler
Thromb Vasc Biol 2000;20(2):290-7.
6. de Beer, F., K. Willems van Dijk, M.C. Jong, L.C. van Vark, A.
van Der Zee, M.H. Hofker, F.J. Fallaux, R.C. Hoeben, A.H. Smelt, L.M.
Havekes. 2000. Apolipoprotein E2 (Lys146-->Gln) causes
hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition
of lipolysis of very low density lipoproteins-triglycerides. Arterioscler.
Thromb. Vasc. Biol. 20:1800
7. Tacken, P.J., B. Teusink, M. C. Jong, D. Harats, L. M. Havekes, K.
Willems van Dijk, M. H. Hofker. 2000. LDL receptor deficiency unmasks altered
VLDL triglyceride metabolism in VLDL receptor transgenic and knockout mice. J.
Lipid Res. 41:2055
1999
1. Willems van Dijk K, Hofker MH, Havekes LM. Dissection of the
complex role of apolipoprotein E in lipoprotein metabolism and
atheosclerosis using mouse models. Current Atherosclerosis Reports
1999;1(2):101-107.
2. Willems van Dijk K, van Vlijmen BJM, de Winther MPJ, van 't Hof B,
van der Zee A, van der Boom H, Havekes LM, Hofker MH. Hyperlipidemia of
APOE2(arg158-cys) and APOE3-Leiden transgenic mice is modulated
predominantly by low density lipoprotein receptor expression. Arterioscler.
Thromb. Vasc . Biol. 1999;19:2945-2951.
3. Willems van Dijk K, van Vlijmen BJ, van't Hof HB, van der Zee A,
Santamarina-Fojo S, van Berkel TJ, Havekes LM, Hofker MH. In LDL
receptor-deficient mice, catabolism of remnant lipoproteins requires a high
level of apoE but is inhibited by excess apoE. J Lipid Res
1999;40(2):336-344.
4. Mensenkamp AR, Jong MC, van Goor H, van Luyn MJ, Bloks V, Havinga
R, Voshol PJ, Hofker MH, van Dijk KW, Havekes LM and others. Apolipoprotein
E participates in the regulation of very low density lipoprotein-triglyceride
secretion by the liver. J Biol Chem 1999;274(50):35711-8.
5. Jong MC, Willems van Dijk K, Dahlmans VE, Van der Boom H,
Kobayashi K, Oka K, Siest G, Chan L, Hofker MH, Havekes LM. Reversal of
hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated
gene delivery of the low-density-lipoprotein receptor, but not by the
very-low-density-lipoprotein receptor. Biochem J 1999;338(Pt
2):281-7.
6. de Winther MPJ, Willems van Dijk K, van Vlijmen BJM, Gijbels MJJ,
Heus JJ, Wijers ER, van den Bos AC, Breuer M, Frants RR, Havekes LM and
others. Macrophage specific overexpression of the human macrophage scavenger
receptor in transgenic mice, using a 180 kb yeast artificial chromosome,
leads to enhanced foam cell formation of isolated peritoneal macrophages. Atherosclerosis
1999;147:339
7. de Winther MP, Gijbels MJ, van Dijk KW, van Gorp PJ, suzuki H,
Kodama T, Frants RR, Havekes LM, Hofker MH. Scavenger receptor deficiency
leads to more complex atherosclerotic lesions in APOE3Leiden transgenic
mice. Atherosclerosis 1999;144(2):315-21.
8. de Beer F, Hendriks WL, van Vark LC, Kamerling SW, Willems van
Dijk K, Hofker MH, Smelt AH, Havekes LM. Binding of beta-VLDL to heparan
sulfate proteoglycans requires lipoprotein lipase, whereas ApoE only
modulates binding affinity. Arterioscler Thromb Vasc Biol
1999;19(3):633-7.
1998
1. Willems van Dijk K, van Vlijmen BJ, van der Zee A, van't Hof B,
van der Boom H, Kobayashi K, Chan L, Havekes LM, Hofker MH. Reversal of
hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden
transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor. Arterioscler
Thromb Vasc Biol 1998;18(1):7-12.
2. Ehnholm S, Willems van Dijk K, van 't Hof B, van der Zee A,
Olkkonen VM, Jauhiainen M, Hofker M, Havekes L, Ehnholm C. Adenovirus
mediated overexpression of human phospholipid transfer protein alters plasma
HDL levels in mice. J Lipid Res 1998;39(6):1248-53.
1996-1997
1. Havekes LM, van Vlijmen BJ, Jong MC, Willems van Dijk K, Hofker MH.
Use of transgenic mice in lipoprotein metabolism and atherosclerosis
research. Prostaglandins Leukot Essent Fatty Acids
1997;57(4-5):463-6.
2. van Vlijmen BJ, Willems van Dijk K, van't Hof HB, van Gorp PJ, van
der Zee A, van der Boom H, Breuer ML, Hofker MH, Havekes LM. In the absence
of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158 --> Cys)
transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein
E*3-Leiden transgenic mice. J.Biol.Chem. 1996;271(48):30595-30602.
3. Jong MC, Dahlmans VE, van Gorp PJ, Willems van Dijk K, Breuer ML,
Hofker MH, Havekes LM. In the absence of the low density lipoprotein
receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits
the hepatic uptake of very low density lipoprotein via a receptor-associated
protein-sensitive pathway. J.Clin.Invest. 1996;98:2259-2267.
.gif){kind=small}
